Genmab A (GMAB) Operating Income Growth (1y) (2019 - 2026)
Genmab A (GMAB) Operating Income Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | 145.20% |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | 1,386.07% |
| 10 | Genmab A | 1.88 Bn | 357.21 Mn | 831.00 Mn | -4.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.26% |
| Sep 30, 2025 | 52.11% |
| Jun 30, 2025 | 55.68% |
| Mar 31, 2025 | 62.07% |
| Sep 30, 2020 | 249,005,935.06% |
| Dec 31, 2019 | -100.00% |